Diabetes Therapies for Dementia

Overview

Journal Curr Neurol Neurosci Rep

Specialty Neurology

Date 2019 Jul 14

PMID 31300920

Citations 14

Authors

Chris Moran

Michele L Callisaya

Velandai Srikanth

Zoe Arvanitakis

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Type 2 diabetes (T2D) is a well-established risk factor for the development of dementia. Dementia and T2D share some underlying pathophysiology that has led to interest in the potential to repurpose drugs used in the management of T2D to benefit brain health. This review describes the scientific data available on the use of T2D medications for the risk reduction or management of dementia, in people with and without T2D.

Recent Findings: Results from basic laboratory research support the potential for commonly-used medications for T2D, including those with direct glucose-lowering properties, to have a beneficial effect on brain health. However, human studies have been mostly observational in nature and report conflicting results. Preliminary data suggest that intranasal insulin, metformin, and GLP-1 agonists show promise for dementia, but confirmatory evidence for their benefit in dementia is still lacking. Current evidence does not support the repurposing of T2D medications for dementia risk reduction or management. Research in the field of T2D and dementia is active, and further data are required before definitive conclusions can be drawn.

Citing Articles

Association between pre-diabetes or diabetes and cognitive impairment in a community-dwelling older population: Bushehr Elderly Health (BEH) program.

Farkhani S, Payab M, Sharifi F, Sharifi Y, Mohammadi S, Shadman Z J Diabetes Metab Disord. 2024; 23(1):639-646.

PMID: 38932839 PMC: 11196454. DOI: 10.1007/s40200-023-01325-y.

Novel targets and therapies of metformin in dementia: old drug, new insights.

Cui W, Lv C, Geng P, Fu M, Zhou W, Xiong M Front Pharmacol. 2024; 15:1415740.

PMID: 38881878 PMC: 11176471. DOI: 10.3389/fphar.2024.1415740.

Validity of Montreal Cognitive Assessment to Detect Cognitive Impairment in Individuals with Type 2 Diabetes.

Gupta A, Goyal A, Rajan R, Vishnu V, Kalaivani M, Tandon N Diabetes Ther. 2024; 15(5):1155-1168.

PMID: 38520603 PMC: 11043253. DOI: 10.1007/s13300-024-01549-y.

Polyoxidovanadates a new therapeutic alternative for neurodegenerative and aging diseases.

Gonzalez-Cano S, Flores G, Guevara J, Morales-Medina J, Trevino S, Diaz A Neural Regen Res. 2023; 19(3):571-577.

PMID: 37721286 PMC: 10581577. DOI: 10.4103/1673-5374.380877.

State of the Science on Brain Insulin Resistance and Cognitive Decline Due to Alzheimer's Disease.

Rhea E, Leclerc M, Yassine H, Capuano A, Tong H, Petyuk V Aging Dis. 2023; 15(4):1688-1725.

PMID: 37611907 PMC: 11272209. DOI: 10.14336/AD.2023.0814.

References

Craft S, Asthana S, Newcomer J, Wilkinson C, Matos I, Baker L . Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry. 1999; 56(12):1135-40. DOI: 10.1001/archpsyc.56.12.1135. View

Gasparini L, Gouras G, Wang R, GROSS R, Beal M, Greengard P . Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci. 2001; 21(8):2561-70. PMC: 6762523. View

Inzucchi S . Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002; 287(3):360-72. DOI: 10.1001/jama.287.3.360. View

Peila R, Rodriguez B, Launer L . Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes. 2002; 51(4):1256-62. DOI: 10.2337/diabetes.51.4.1256. View

During M, Cao L, Zuzga D, Francis J, Fitzsimons H, Jiao X . Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003; 9(9):1173-9. DOI: 10.1038/nm919. View

Reger M, Watson G, Frey 2nd W, Baker L, Cholerton B, Keeling M . Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging. 2005; 27(3):451-8. DOI: 10.1016/j.neurobiolaging.2005.03.016. View

Biessels G, Staekenborg S, Brunner E, Brayne C, Scheltens P . Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2005; 5(1):64-74. DOI: 10.1016/S1474-4422(05)70284-2. View

Ryan C, Freed M, Rood J, Cobitz A, Waterhouse B, Strachan M . Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care. 2006; 29(2):345-51. DOI: 10.2337/diacare.29.02.06.dc05-1626. View

Singh S, Loke Y, Furberg C . Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007; 298(10):1189-95. DOI: 10.1001/jama.298.10.1189. View

10.

El-Mir M, Detaille D, R-Villanueva G, Delgado-Esteban M, Guigas B, Attia S . Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons. J Mol Neurosci. 2007; 34(1):77-87. DOI: 10.1007/s12031-007-9002-1. View

11.

Reger M, Watson G, Green P, Baker L, Cholerton B, Fishel M . Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis. 2008; 13(3):323-31. PMC: 2804944. DOI: 10.3233/jad-2008-13309. View

12.

Chiu S, Chen C, Cline H . Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. Neuron. 2008; 58(5):708-19. PMC: 3057650. DOI: 10.1016/j.neuron.2008.04.014. View

13.

Zhao W, Townsend M . Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim Biophys Acta. 2008; 1792(5):482-96. DOI: 10.1016/j.bbadis.2008.10.014. View

14.

Chen Y, Zhou K, Wang R, Liu Y, Kwak Y, Ma T . Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci U S A. 2009; 106(10):3907-12. PMC: 2656178. DOI: 10.1073/pnas.0807991106. View

15.

Lovshin J, Drucker D . Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol. 2009; 5(5):262-9. DOI: 10.1038/nrendo.2009.48. View

16.

Abbas T, Faivre E, Holscher C . Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease. Behav Brain Res. 2009; 205(1):265-71. DOI: 10.1016/j.bbr.2009.06.035. View

17.

Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T . Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging. 2009; 32(9):1626-33. DOI: 10.1016/j.neurobiolaging.2009.10.009. View

18.

Gupta A, Bisht B, Dey C . Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology. 2011; 60(6):910-20. DOI: 10.1016/j.neuropharm.2011.01.033. View

19.

Hsu C, Wahlqvist M, Lee M, Tsai H . Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis. 2011; 24(3):485-93. DOI: 10.3233/JAD-2011-101524. View

20.

McClean P, Parthsarathy V, Faivre E, Holscher C . The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci. 2011; 31(17):6587-94. PMC: 6622662. DOI: 10.1523/JNEUROSCI.0529-11.2011. View